About ALIVE Laboratories

Management Team

• Albert P. Li, Ph. D. and M. B. A. show/hide bio
  Albert Li serves as President and Chief Executive Officer of the company. Dr. Li is an internationally renowned expert in the isolation, culturing, cryopreservation of hepatocytes as well as the application of in vitro experimental systems in the evaluation of xenobiotic metabolism, drug-drug interactions, and xenobiotic toxicity. Dr. Li obtained his Ph. D. (Biomedical Sciences) in 1976 from the University of Tennessee, Oak Ridge Graduate School of Biomedical Sciences. Dr. Li previous was a research cell biologist with LRRI (1979-1981), Senior Research Fellow and Head of Liver Biology in Monsanto Company, St. Louis, Missouri (1981-1993), Research Professor and Director of the Surgical Research Institute, St. Louis University Medical School (1993-1995), Chief Scientific Officer of In Vitro Technologies Inc. (now Celsis Inc.; Baltimore, Maryland; 1995-2002), President and Chief Executive Officer of Phase I Molecular Toxicology, Santa Fe, New Mexico (2002 – 2004), and Co-founder and President and Chief Executive Officer of three inter-related companies: Advanced Pharmaceutical Sciences Inc./In Vitro ADMET Laboratories LLC, Columbia, Maryland, and BRIVAL Inc., Vancouver, Maryland.
• Robert Rubin, Ph. D. show/hide bio
  Dr. Rubin received degrees from Cornell College, The University of Michigan, and Michigan State University with a Post Doctoral fellowship at the University of Colorado, Boulder. He was trained as a cell biologist and functioned as such on NIH and other grants for 15 years before assuming the position of Vice President for Research at the University of Miami (UM). There he assumed the duties equivalent to that of COO of the academic medical Center in Miami (UM/Jackson Memorial Medical Center). During his tenure there, sponsored programs increased from $33M to $150M per year, with associated increases in physical plant and personnel. In 1996, Dr. Rubin moved to Albuquerque to assume the position of President and CEO of the Lovelace Respiratory Research Institute. There he defined a new mission for the organization and engineered the transition of federal lab (Inhalation Toxicology labs) to become an integral division of LRRI in the most successful privatization of a DOE facility in the history of the agency. Under his leadership, LRRI has become a leading institution for research in the causes and treatment of respiratory diseases, with a broad funding base of NIH, EPA, DOD, and industry support, collaborations with other highly regarded organizations, and state-of-the-art infrastructure and capabilities.

Technical Team

• Albert P. Li, Ph. D. and M. B. A. show/hide bio
  Albert Li serves as President and Chief Executive Officer of the company. Dr. Li is an internationally renowned expert in the isolation, culturing, cryopreservation of hepatocytes as well as the application of in vitro experimental systems in the evaluation of xenobiotic metabolism, drug-drug interactions, and xenobiotic toxicity. Dr. Li obtained his Ph. D. (Biomedical Sciences) in 1976 from the University of Tennessee, Oak Ridge Graduate School of Biomedical Sciences. Dr. Li previous was a research cell biologist with LRRI (1979-1981), Senior Research Fellow and Head of Liver Biology in Monsanto Company, St. Louis, Missouri (1981-1993), Research Professor and Director of the Surgical Research Institute, St. Louis University Medical School (1993-1995), Chief Scientific Officer of In Vitro Technologies Inc. (now Celsis Inc.; Baltimore, Maryland; 1995-2002), President and Chief Executive Officer of Phase I Molecular Toxicology, Santa Fe, New Mexico (2002 – 2004), and Co-founder and President and Chief Executive Officer of three inter-related companies: Advanced Pharmaceutical Sciences Inc./In Vitro ADMET Laboratories LLC, Columbia, Maryland, and BRIVAL Inc., Vancouver, Maryland.
• JeanClare Seagrave, Ph. D. show/hide bio
  JeanClare Seagrave is the principal investigator for ALIVE, LLC. Her interests focus on comparison of in vivo and in vitro toxicology and physiology, particularly the validation of in vitro techniques for pre-clinical testing and cross-species comparisons. She obtained her BS from the California Institute of Technology in 1976, and her PhD in Biomedical Sciences from the University of New Mexico in 1981. In a postdoctoral fellowship in the Genetics Division of Los Alamos National Laboratories her research focused on toxicity of heavy metals. She then joined the faculty of the University of New Mexico, Department of Pathology, working on regulation and biochemical pathways involved in mast cell activation. She joined the Lovelace organization in 1988. Her interests focus on comparison of in vivo and in vitro toxicology and physiology, particularly the validation of in vitro techniques for pre-clinical testing and cross-species comparisons.
• Adriana Kajon, Ph. D.
• Yumiko LaForge, B. Sc. show/hide bio
  Yumiko LaForge received her Bachelor of Science degree from West Virginia University in Animal and Veterinary Science in 1999. She has extensive experience in preparation and cryopreservation of primary cells. Her experience and expertise focus on in vitro ADMET and biochemical assays, including analysis of cytochrome P450 isozymes and analysis of xenobiotic metabolism in human hepatocytes. She currently serves as the Vice President for Laboratory Operations for APSciences and for ALIVE.